AVGR(Delisted)
Avinger·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 1
Bearish signal 2
Low Cash Short-term Debt Ratio
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About AVGR
Avinger, Inc.
A medical device company that develops and commercializes image-guided, catheter-based systems to treat peripheral artery disease
400 Chesapeake Drive, Redwood City , California 94063
--
Avinger, Inc., was incorporated in Delaware on March 8, 2007. The company is a commercial-stage medical device company that designs, manufactures and sells real-time high-definition image-guided, minimally invasive catheter-based systems for physicians to treat patients with peripheral arterial disease (PAD). PAD patients have a large number of plaques in their arteries that supply blood to areas far from the heart, especially the pelvis and legs. The company's mission is to significantly improve the treatment of vascular diseases by launching products based on the Lumivascular platform, the only intravascular real-time high-definition image guidance system available in the market.
Company Financials
EPS
AVGR has released its 2024 Q1 earnings. EPS was reported at -2.49, versus the expected -1.35, missing expectations. The chart below visualizes how AVGR has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
AVGR has released its 2024 Q3 earnings report, with revenue of 1.65M, reflecting a YoY change of -9.19%, and net profit of -3.71M, showing a YoY change of 17.20%. The Sankey diagram below clearly presents AVGR's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
No Data
You can ask Aime
No Data
